A Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Pollen Allergy

Inclusion Criteria: * Subject who has medical history of nasal symptoms (sneezing, itching, rhinorrhoea, and congestion), and/or eye symptoms (itching, redness, and lacrimation) at least in 2 cedar pollen dispersion seasons prior to the screening test. * Subject who had the Japanese cedar pollen-specific antibody test result of Class 3 or higher in the allergy test at screening. * Subject who had a positive prick test result for Japanese cedar pollen in the screening test. * Subject whose past and present medical conditions are considered medically stable. Exclusion Criteria: * Subject who had the test result of IgE antibody specific to other antigen than Japanese cedar pollen * Subject who is scheduled to receive other vaccination during the primary study period. * Subject who has received or is planning to receive vaccination of live vaccine within 28 days prior to the first vaccination of the study drug, and/or a subject who has received or is planning to receive vaccination of inactivated vaccine/toxoid within 7 days prior to the first vaccination of the study drug. * Subject who received specific immunotherapy for cedar pollinosis in the past. * Subject who received specific or non-specific immunotherapy within 5 years prior to the screening test. * Subject who has used the following drug(s) prior to the first vaccination of the study drug: * Within 56 days prior to the first vaccination of the study drug: Topical steroid, histamine H1-receptor antagonist, chemical mediator-isolation inhibitor, Th2 cytokine inhibitor, thromboxane A2 synthesis inhibitor, thromboxane A2 receptor antagonist, and/or leukotriene receptor antagonist * Within 84 days prior to the first vaccination of the study drug: Systemic steroid, and antibody drugs (including anti-TNF-alpha antibody and anti-IgE monoclonal antibody) * Subject who has history of allergic reactions such as anaphylactic shock and exanthema generalized caused by food and/or medical products (including vaccine) in the past, and/or a subject who had a fever of 39.0 degrees Celsius or higher within 2 days after the previous vaccination. * Subject who has evidently high fever (37.5 degrees Celsius or higher) on the day of vaccination, or subject who has severe acute disease. * Subject who meets any of the following criteria for laboratory and other tests at screening. The reference range for each test is the range used in the study site. * Blood biochemistry test: 1. AST (GOT) or ALT (GPT) value over 100 IU/L 2. Creatinine value over 1.5 mg/dL * Urine drug screening: 1\. Subject who had a positive drug test result for: benzodiazepines, cocaine and similar narcotics, stimulant drugs, cannabis, barbituric acids, morphine and similar narcotics, PCPs, or tricyclic antidepressants. * Immunological test: 1. Subject who had a positive test results for HBs antigen, HCV antibody, or HIV antigen/antibody * Subject who has autoimmune disease or other serious primary disease. * Subject who was diagnosed with immunodeficiency in the past. * Subject who has a complication of perennial allergic rhinitis, rhinitis medicamentosa, or non-allergic rhinitis which requires medical treatment. * Subject who has a complication of cardiovascular disease (including cardiac failure congestive, angina pectoris, and cardiac arrhythmias which requires medical treatment). * Subject who has a complication of hepatic disease (including hepatitis viral and drug-induced liver injury). * Subject who has a complication of renal disease (including acute kidney injury, glomerulonephritis, and nephritis interstitial, but not including medical history of calculus). * Subject who has a complication of respiratory disease (including asthma bronchial which requires medical treatment, and bronchitis chronic, but not including medical history of asthma in the childhood). * Subject has a complication of malignant tumor or has been diagnosed or has received treatment for malignant tumor within 5 years prior to the first vaccination of the study drug. * Subject who was diagnosed with schizophrenia, other mental conditions including bipolar disorder and major depressive disorder, or dementia, or a subject who has received drug(s) for the treatment of dementia. * Subject who has a complication of dermatitis atopic. * Subject who has a complication which may have an impact on the results of the local and systemic reaction or prick test assessment. * Subject who has received a vaccination of Cryj2-LAMP vaccine.